First-in-human, proof-of-concept phase I trial evaluating the tolerability, pharmacokinetics and efficacy of RG 101 in healthy volunteers and in patients with hepatitis C

Trial Profile

First-in-human, proof-of-concept phase I trial evaluating the tolerability, pharmacokinetics and efficacy of RG 101 in healthy volunteers and in patients with hepatitis C

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Mar 2017

At a glance

  • Drugs RG 101 (Primary) ; Simeprevir
  • Indications Hepatitis C
  • Focus Adverse reactions; First in man; Proof of concept
  • Sponsors Regulus Therapeutics
  • Most Recent Events

    • 11 Mar 2017 Results assessing immune phenotype and function of NK and T cells (n=32), published in the Hepatology
    • 10 Jan 2017 Results assessing safety and tolerability, pharmacokinetics, and antiviral effect of a single dose of RG-101 in patients with chronic HCV infection (n=32) published in the Lancet.
    • 17 Apr 2016 Sequence analysis for resistance monitoring of 32 patients were presented at The International Liver Congress™ 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top